AAV mediated influenza vaccines

US10786568B2 · kind B2 · utility

Assignees

• The Trustees of the University of Pennsylvania · US
• JANSSEN BIOTECH, INC. · US

Inventors

• Maria P. Limberis · Philadelphia, US
• Anna P. Tretiakova · Philadelphia, US
• James M. Wilson · Glen Mills, US
• Michael Naso · Union, US
• Joost Alexander Kolkman · Maarn, NL
• Robert Heinz Edward Friesen · Wassenaar, NL
• Qiang Wang · Philadelphia, US

Key dates

• Filing date: Feb 27, 2018
• Grant date: Sep 29, 2020
• Expiry date: Feb 27, 2038

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2840/203
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A non-replicating recombinant adeno-associated associated virus (rAAV) having an AAV capsid having packaged therein a vector genome which comprises AAV inverted terminal repeat sequences and at least one nucleic acid sequence encoding four different immunoglobulin regions (a), (b), (c) and (d) is provided. The rAAV-expressed immunoglobulins are useful for providing passive immunization against influenza A and influenza B. Also described herein are compositions containing the rAAV. Methods of vaccinating patients against influenza are provided.